These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399 [TBL] [Abstract][Full Text] [Related]
24. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy. Dalo JD; Weisman ND; White CM Ann Pharmacother; 2023 Apr; 57(4):489-502. PubMed ID: 35950315 [TBL] [Abstract][Full Text] [Related]
25. A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy. Sawan MA; Prabakaran S; D'Souza M; Behbahani-Nejad O; Gold ME; Williams BR; Bilen O Clin Cardiol; 2024 Jan; 47(1):e24207. PubMed ID: 38269637 [TBL] [Abstract][Full Text] [Related]
26. [Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy]. Argirò A; Zampieri M; Marchi A; Del Franco A; Pàlinkàs ED; Biagioni G; Chiti C; Mazzoni C; Fornaro A; Targetti M; Cappelli F; Olivotto I G Ital Cardiol (Rome); 2023 Oct; 24(10):792-799. PubMed ID: 37767831 [TBL] [Abstract][Full Text] [Related]
27. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706 [TBL] [Abstract][Full Text] [Related]
28. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Woodland M; Al-Horani RA Cardiovasc Hematol Agents Med Chem; 2023; 21(2):78-83. PubMed ID: 36278454 [TBL] [Abstract][Full Text] [Related]
29. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management. Sykuta A; Yoon CH; Baldwin S; Rine NI; Young M; Smith A Ann Pharmacother; 2024 Mar; 58(3):273-285. PubMed ID: 37329113 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study. Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260 [TBL] [Abstract][Full Text] [Related]
32. Contemporary Surgical Management of Hypertrophic Cardiomyopathy. Schaff HV; Wei X Ann Thorac Surg; 2024 Feb; 117(2):271-281. PubMed ID: 37914148 [TBL] [Abstract][Full Text] [Related]
33. Mavacamten decreases maximal force and Ca Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957 [TBL] [Abstract][Full Text] [Related]
34. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy. Chase Cole J; Benvie SF; DeLosSantos M Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915 [TBL] [Abstract][Full Text] [Related]
35. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Marian AJ Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830 [TBL] [Abstract][Full Text] [Related]
37. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641 [TBL] [Abstract][Full Text] [Related]
38. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531 [TBL] [Abstract][Full Text] [Related]
39. Surgical pathology of subaortic septal myectomy: histology skips over clinical diagnosis. Abecasis J; Gouveia R; Castro M; Andrade MJ; Ribeiras R; Ramos S; Abecasis M; Cardim N; Gil V Cardiovasc Pathol; 2018; 33():32-38. PubMed ID: 29414430 [TBL] [Abstract][Full Text] [Related]
40. Computed tomography imaging to quantify the area of the endocardial subvalvular apparatus in hypertrophic cardiomyopathy - Relationship to outflow tract obstruction and symptoms. Tajima M; Iguchi N; Utanohara Y; Hiroi Y; Mahara K; Niwa T; Takayama M; Sumiyoshi T; Tomoike H J Cardiovasc Comput Tomogr; 2016; 10(5):351-8. PubMed ID: 27498132 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]